Build status - In Progress
Found 94 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
PROOF-HD is a placebo-controlled (double blind) multicenter Phase 3 trial of Pridopidine in Huntington Disease patients. Recruitment: 480 participants at 60 sites, a target of 8 participants per site. Procedures include administration of study drug or placebo in tablet form twice daily for a period of 67-80 weeks with option …
Efficacy of nipocalimab in patients with warm autoimmune hemolytic anemia (wAIHA) Durable response in improvement in hemoglobin (Hgb), defined as attainment of the following at 3 consecutive visits, where at least the first is at or before Week 16, without the need of rescue therapy: 1- Hgb concentration greater than …
The purpose of this study is to find out if the investigational drug, apraglutide and investigational drug , is able to reduce the volume per week of PS required in adults with short bowel syndrome and intestinal failure.
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
A study to evaluate posoleucel (ALVR105); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus. We would like to rely on WCG as the IRB of record for this study.
To compare the effect of mitapivat versus placebo on transfusion burden in subjects with alpha- or beta-transfusiondependent thalassemia (TDT) Transfusion reduction response (TRR), defined as a 50% reduction in transfused red blood cell (RBC) units with a reduction of greater that or equal to 2 units of transfused RBCs in …
dosing of ABC008 in subjects with inclusion body myositis (IBM).
Please choose between Voice or SMS based delivery of verification code
or